Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jan 30;5(1):e276.
doi: 10.1038/bcj.2014.97.

The treatment-related mortality score is associated with non-fatal adverse events following intensive AML induction chemotherapy

S A Buckley  1 , M Othus  2 , E H Estey  3 , R B Walter  4
Affiliations

The treatment-related mortality score is associated with non-fatal adverse events following intensive AML induction chemotherapy

S A Buckley et al. Blood Cancer J. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Higher TRM scores are associated with early non-fatal adverse events after AML induction therapy. Kaplan–Meier estimates of freedom from infection (a,c) and requirement for ICU care (b,d) in our cohort, stratified by quartiles or median of TRM score, from the first day of induction chemotherapy until day 28; patients who received salvage chemotherapy were censored on the first day of initiation of such therapy. In our cohort, high TRM scores were significantly associated with infection (Ptrend=0.006) and ICU transfer (Ptrend=0.003), particularly when the cohort was stratified by median TRM score of 4.67 (P=0.02, P=0.0004, respectively).
See this image and copyright information in PMC

References

    1. Othus M, Kantarjian H, Petersdorf S, Ravandi F, Godwin J, Cortes J et al. Declining rates of treatment-related mortality in patients with newly diagnosed AML given 'intense' induction regimens: a report from SWOG and MD Anderson. Leukemia 2014; 28: 289–292. - PMC - PubMed
    1. Pagano L, Caira M, Rossi G, Tumbarello M, Fanci R, Garzia MG et al. A prospective survey of febrile events in hematological malignancies. Ann Hematol 2012; 91: 767–774. - PubMed
    1. Walter RB, Estey EH. Management of older or unfit patients with acute myeloid leukemia. Leukemia 2014, e-pub ahead of print 9 July 2014; doi:10.1038/leu.2014.216. - PMC - PubMed
    1. Walter RB, Othus M, Borthakur G, Ravandi F, Cortes JE, Pierce SA et al. Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. J Clin Oncol 2011; 29: 4417–4423. - PMC - PubMed
    1. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis 2011; 52: e56–e93. - PubMed

Publication types